Vivos Therapeutics, Inc.

Equities

VVOS

US92859E2072

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
2.72 USD +2.26% Intraday chart for Vivos Therapeutics, Inc. -1.81% -78.14%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures MT
Top Premarket Decliners MT
Transcript : Vivos Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024
Vivos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (VVOS) VIVOS THERAPEUTICS Posts Q4 Revenue $3.2M MT
Vivos Therapeutics, Inc. Receives FDA Clearance to Vivos Care Oral Appliances to Treat Severe OSA in Adults CI
Vivos Therapeutics, Inc. Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA CI
Top Premarket Decliners MT
Health Care Drops Amid Skepticism About Cigna, Humana Deal -- Health Care Roundup DJ
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Top Midday Gainers MT
Sector Update: Health Care Stocks Advance in Afternoon Trading MT
Vivos Therapeutics Receives FDA 510(k) Clearance for Oral Device Treatment for Sleep Apnea; Shares Soar MT
Vivos Therapeutics Shares More than Double on FDA's 510(k) Clearance for Sleep Apnea Treatment DJ
Upward Revision to Q3 GDP, Dovish Fed Signals Drive Premarket Gains for US Equity Futures MT
US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea RE
Vivos Therapeutics, Inc. Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea CI
Transcript : Vivos Therapeutics, Inc., Q3 2023 Earnings Call, Nov 14, 2023
Vivos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (VVOS) VIVOS THERAPEUTICS Reports Q3 Revenue $3.3M, vs. Street Est of $4.14M MT
Vivos Therapeutics, Inc. announced that it has received $4.000003 million in funding CI
Vivos Therapeutics, Inc. announced that it expects to receive $4.000003 million in funding CI
Vivos Therapeutics Signs Up NOUM as Exclusive Distribution Partner for MENA Region MT
US Equity Markets Close Higher Wednesday After Ousting of House Speaker MT
Sector Update: Health Care Stocks Advancing Late Afternoon MT
Chart Vivos Therapeutics, Inc.
More charts
Vivos Therapeutics, Inc. is a medical technology company. The Company is focused on the development and commercialization of a suit of diagnostic and multi-disciplinary treatment modalities for patients with cranial and/or dentofacial abnormalities and the array of medical conditions, including mild to moderate obstructive sleep apnea (OSA) and snoring in adults. The Company's Vivos Method is a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities and/or mild to moderate OSA and snoring. The Company's program is to train dentists and offer them other value-added services in connection with their ordering and use of the Vivos System for patients is called the Vivos Integrated Practice program. The Vivos Method comprises of various products and services, such as Vivos Complete Airway Repositioning and/or Expansion (CARE) oral appliance therapy; VivosGuides;Vivos Versa; POD and Night Block, and VivosMyoCorrect.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.66 USD
Average target price
7.225 USD
Spread / Average Target
+171.62%
Consensus
  1. Stock Market
  2. Equities
  3. VVOS Stock
  4. News Vivos Therapeutics, Inc.
  5. Vivos Therapeutics Enters Into Distribution Agreement With GM Instruments for US, Canada